YHO-13177: A Potent BCRP Inhibitor for Research and Pharmaceutical Applications
Explore the capabilities of YHO-13177, a key tool in understanding and overcoming drug resistance in cancer research.
Get a Quote & SampleProduct Core Value
YHO-13177
YHO-13177 is a research chemical that functions as a potent and specific inhibitor of Breast Cancer Resistance Protein (BCRP/ABCG2). Its primary value lies in its ability to modulate drug efflux, a critical factor in multidrug resistance (MDR) observed in various cancers. By inhibiting BCRP, YHO-13177 can re-sensitize cancer cells to chemotherapeutic agents, making it a valuable tool for researchers investigating these mechanisms.
- Understanding YHO-13177 BCRP inhibitor mechanisms provides critical insights into cellular drug transport and resistance pathways.
- The unique properties of YHO-13177 CAS 912287-56-0 make it essential for studies on how BCRP influences cancer drug efficacy.
- Leveraging YHO-13177 for cancer therapy research opens avenues for developing more effective treatment strategies against resistant tumors.
- Acquiring YHO-13177 from reliable suppliers is crucial for ensuring the quality and consistency needed in scientific experimentation.
Key Advantages
Enhanced Drug Efficacy
YHO-13177 potentiates the cytotoxicity of common chemotherapeutic agents like SN-38, mitoxantrone, and topotecan by preventing their efflux from cancer cells, a key aspect of BCRP ABCG2 inhibitor action.
Specificity in Action
The compound shows specificity, enhancing drug efficacy without significantly affecting P-glycoprotein-mediated resistance, which is crucial for targeted research into drug resistance mechanisms in oncology.
Research Versatility
As a vital tool for biochemical tools for drug discovery, YHO-13177 aids in understanding cellular drug transport and developing novel therapeutic interventions.
Key Applications
Oncology Research
Utilizing YHO-13177 for cancer therapy research is instrumental in developing strategies to combat drug-resistant cancers.
Mechanism Studies
Investigating YHO-13177 BCRP inhibitor mechanisms helps elucidate complex drug resistance pathways.
Drug Development
Serving as a critical pharmaceutical intermediate, it supports the development of next-generation anticancer drugs.
Biochemical Assays
Its precise action makes YHO-13177 essential for various in vitro and in vivo biochemical assays related to drug transport.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).